NEW YORK, May 29, 2014 (GLOBE NEWSWIRE) -- Premune, a research and development stage animal health company focused on the development of new therapeutics for companion animals, today announced the appointment of Eileen Daloia as Head of Regulatory Affairs. Ms. Daloia, who will be based in Premune's New York office and report directly to CEO Viktor Karlsson, will oversee all regulatory initiatives associated with the approval of the Company's veterinary treatment product candidates. Ms. Daloia is the third senior-level hire since the Company announced its U.S. subsidiary on April 15, 2014, joining Michio Soga, CFO and Mickey McDermott, Global Head of Marketing.
"Eileen has a wealth of direct regulatory experience in the veterinary arena and brings a strategic, scientific and global mindset to the ongoing development efforts of Premune. Her skills and expertise make Eileen another important addition to our growing management team as we continue building our corporate infrastructure both in Sweden and the U.S.," said Premune CEO and co-founder, Viktor Karlsson. "With more than a decade of veterinary health experience, Eileen's efforts have led to regulatory approvals for multiple companion animal drugs, and we believe that this relevant expertise will prove invaluable as we advance our product candidates. We are excited to have Eileen onboard and look forward to her contributions."
Eileen Daloia joins Premune with more than 13 years of regulatory affairs experience in the animal health space. Most recently, she was Director, Regulatory Affairs – US and Canadian Divisions for Virbac Animal Health, where she contributed to a number of New Animal Drug Application ("NADA") and Minor Use Minor Species ("MUMS") approvals during her three years in the position. She helped establish Virbac's U.S. and Canada regulatory strategy and served as a direct liaison with the FDA and other global regulators. Previously, Eileen was Manager of Regulatory Affairs at Hanford Pharmaceuticals, a contract manufacturer providing product development and support services for the pharmaceutical industry. Previous to Hanford Pharmaceuticals where she spent 10 years, Eileen was a researcher at Bristol-Myers Squibb. Eileen holds a BA in Chemistry from Wells College and is a Licensed Practical Nurse.
"I am excited to be joining such a focused, entrepreneurial company with what I believe is a promising pipeline of product candidates. There are interesting possibilities that lie in our future and I believe that Premune is well positioned to break new ground in the companion animal health market. I look forward to joining this team and lending my expertise to Premune's regulatory efforts going forward," added Daloia.
With its solid foundation in immunology and inflammatory disease research, Premune's pipeline of compounds in development seeks to target several of the most prevalent problem areas in companion animal health. In this vein, the Company is working to develop the world's first preventive treatment for pet allergies.
Premune is a research and development stage animal health company focused on the development and commercialization of novel therapeutics for the treatment and prevention of some of the most common conditions affecting companion animals. The Company's pipeline of compounds under development seeks to target indications such as allergies and inflammatory diseases that are highly prevalent in cats and dogs. Premune's current product candidates are the result of decades of collective research in bacteriology and immunology at the University of Gothenburg, one of Sweden's leading academic institutions. Premune's pipeline consists of compounds in various stages of clinical development. The Company is continuously seeking to expand its therapeutic portfolio through a combination of in-house research and development projects in conjunction with its academic partners and the strategic in-licensing of additional product candidates. The Company's in-licensing strategy is to identify therapeutic entities in development for humans that exhibit potential efficacy in companion animals as well. Premune aims to advance these products through clinical development and bring them to market in veterinary pharmaceutical and nutraceutical arenas. Premune´s goal is to improve the quality of life for companion animals worldwide by translating leading human research to pets.
Forward-Looking and Cautionary Statements
Statements contained in this release may constitute "forward-looking statements". These statements may be identified by words such as "expects," "looks forward to," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," "project" or words of similar meaning. Such statements are based on the current expectations and certain assumptions of Premune's management and are subject to certain risks and uncertainties. A variety of factors, many of which are beyond Premune's control, can affect the operations, performance, development of products, business strategy, timing and results. Without limiting the foregoing, the development, testing, regulatory approval process and the timeline associated with development, manufacture and sale of therapeutic products in the animal health industry are inherently uncertain. Premune is neither required nor intends to publicly update or revise any forward-looking statements.